keyword
MENU ▼
Read by QxMD icon Read
search

cancer and venous thromboembolism

keyword
https://www.readbyqxmd.com/read/28525975/venous-thromboembolism-in-hospitalized-patients-receiving-chemotherapy-for-malignancies-at-japanese-community-hospital-prospective-observational-study
#1
Hiromitsu Kitayama, Tomohiro Kondo, Junko Sugiyama, Kazutomo Kurimoto, Yasuhiro Nishino, Michiaki Hirayama, Yasushi Tsuji
BACKGROUND: Although Asian population was recognized to have a lower risk of venous thromboembolism (VTE), its increasing prevalence and incidence remain unclear in patients with malignancies. We attempted to predict VTE development using activation markers of coagulation and fibrinolysis. METHODS: We enrolled patients with malignancy admitted to Tonan Hospital between April and December 2014 to receive a new-for-them chemotherapy regimen. All patients were examined for VTE by computed tomography and whole-leg compression ultrasonography before chemotherapy and three months later...
May 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28517021/low-discriminating-power-of-the-modified-ottawa-vte-risk-score-in-a-cohort-of-patients-with-cancer-from-the-riete-registry
#2
Adriano Alatri, Lucia Mazzolai, Carme Font, Alfonso Tafur, Reina Valle, Pablo Javier Marchena, Aitor Ballaz, Eros Tiraferri, Llorenç Font, Manuel Monreal
Treatment of patients with cancer-associated venous thromboembolism (VTE) remains a major challenge. The modified Ottawa score is a clinical prediction rule evaluating the risk of VTE recurrences during the first six months of anticoagulant treatment in patients with cancer-related VTE. We aimed to validate the Ottawa score using data from the RIETE registry. A total of 11,123 cancer patients with VTE were included in the analysis. According to modified Ottawa score, 2,343 (21 %) were categorised at low risk for VTE recurrences, 4,525 (41 %) at intermediate risk, and 4,255 (38 %) at high risk...
May 18, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28516316/venous-thromboembolism-after-nephrectomy-incidence-timing-and-associated-risk-factors-from-a-national-multi-institutional-database
#3
Brian J Jordan, Richard S Matulewicz, Brian Trihn, Shilajit Kundu
PURPOSE: To evaluate the rate of venous thromboembolism (VTE) after nephrectomy with specific focus on event timing and location (before or after hospital discharge) in order to identify modifiable risk factors and establish benchmarks for preventive interventions. METHODS: Using the ACS-NSQIP database, we identified patients undergoing nephrectomy from 2006 to 2012. Patients were analyzed in two cohorts: collectively and by surgical approach [open vs. lap/robotic (MIS)]...
May 17, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28515116/antidepressants-depression-and-venous-thromboembolism-risk-large-prospective-study-of-uk-women
#4
Lianne Parkin, Angela Balkwill, Siân Sweetland, Gillian K Reeves, Jane Green, Valerie Beral
BACKGROUND: Some investigators have reported an excess risk of venous thromboembolism (VTE) associated with depression and with use of antidepressant drugs. We explored these associations in a large prospective study of UK women. METHODS AND RESULTS: The Million Women Study recruited 1.3 million women through the National Health Service Breast Screening Programme in England and Scotland. Three years after recruitment, women were sent a second questionnaire that enquired about depression and regular use of medications in the previous 4 weeks...
May 17, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28508916/direct-oral-anticoagulants-for-the-treatment-of-cancer-associated-venous-thromboembolism-what-do-we-know-so-far
#5
Minna Voigtlaender, Florian Langer
Cancer patients with venous thromboembolism (VTE) are at increased risk for both bleeding and VTE recurrence. Anticoagulation with low-molecular-weight heparin (LMWH) is the standard of care during the initial and long-term treatment phase (i.e. during the first 3 - 6 months of therapy) based on its overall beneficial safety and efficacy profile compared to vitamin K antagonists (VKAs). The direct oral anticoagulants (DOACs) rivaroxaban, apixaban, edoxaban, and dabigatran are approved for the treatment of acute VTE, and the combined six phase-3 trials have included > 1500 patients with active cancer, as defined by variable selection criteria...
May 16, 2017: Hämostaseologie
https://www.readbyqxmd.com/read/28508703/increased-risk-of-arterial-thromboembolic-events-with-combination-lenalidomide-dexamethasone-therapy-for-multiple-myeloma
#6
Satish Maharaj, Simone Chang, Karan Seegobin, Ivan Serrano-Santiago, Lara Zuberi
Cancer associated thrombosis is a leading cause of morbidity and mortality. Research and guidelines have focused on venous thromboembolic events (VTE). Within the past decade, combination lenalidomide and dexamethasone has become a standard of therapy for multiple myeloma and is now widely used. In these patients, the risk of arterial thromboembolic events (ATE) has not been addressed to the same extent as VTE. Areas discussed: Presented is a targeted review of published data on ATE in MM patients on combination lenalidomide/dexamethasone therapy...
May 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28502867/screening-for-occult-cancer-in-idiopathic-venous-thromboembolism-systemic-review-and-meta-analysis
#7
Alina Klein, Daniel Shepshelovich, Galia Spectre, Hadar Goldvaser, Pia Raanani, Anat Gafter-Gvili
BACKGROUND: Idiopathic venous thromboembolism (VTE) may be associated with an occult malignancy. Early detection of cancer might be translated to a better prognosis for these patients. However, the efficacy of extensive screening for cancer in patients with idiopathic VTE is controversial. MATERIALS AND METHODS: Systemic review and meta-analysis of all available prospective trials comparing extensive to limited screening for occult malignancies in patients with idiopathic VTE...
May 11, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28498242/rivaroxaban-used-in-the-treatment-patients-with-gynecologic-cancer-and-venous-thromboembolism-the-experience-of-instituto-nacional-de-c%C3%A3-ncer-rio-de-janeiro-brazil
#8
Marcos José Pereira Renni, Mário Lúcio Cordeiro Araujo, Ingrid Trugilho, Anke Bergmann, Carla Patricia de Morais E Coura
INTRODUCTION: Venous thromboembolism (VTE) is a major complication of malignant diseases and is a frequent cause of death in patients with cancer. Managing anticoagulation in these patients is challenging because of the high risk of recurrent VTE and bleeding events. Rivaroxaban is an oral anticoagulant that provides rapid onset of anticoagulation. OBJECTIVE: The aim of this study was to describe the complications of rivaroxaban and potentially associated factors in patients with gynecologic cancer and VTE...
June 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28492054/a-review-of-hormone-based-therapies-to-treat-adult-acne-vulgaris-in-women
#9
REVIEW
M K Trivedi, K Shinkai, J E Murase
Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women. Our objective is to provide a concise and comprehensive overview of the types of hormonal therapy that are available to treat acne and comment on their efficacy and safety profiles for clinical practice. A systematic search using the PubMed Database was conducted to yield 36 relevant studies for inclusion in the review and several conclusions were drawn from the literature...
March 2017: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/28490886/apatinib-to-combat-egfr-tki-resistance-in-an-advanced-non-small-cell-lung-cancer-patient-with-unknown-egfr-status-a-case-report
#10
Yanmei Peng, Huijuan Cui, Zhe Liu, Daiwei Liu, Fan Liu, Yazhong Song, Hua Duan, Yuqin Qiu, Qiang Li
Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)-directed therapies are widely used. In the former category, the agent erlotinib (tyrosine kinase inhibitor) has shown obvious advantages over cytotoxic therapy. Anti-VEGF therapy bevacizumab used for lung adenocarcinoma was recommended in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as first-line therapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28490684/-cerebral-venous-sinus-thrombosis-following-cisplatin-based-chemotherapy-for-testicular-tumor
#11
Manabu Ishihara, Koichi Satoh, Mami Hanaoka, Kazuhito Matsuzaki, Taku Matsuda, Hajimu Miyake, Hitoshi Niki
A man in his 30s who presented with an enlarged right testicle was diagnosed with a germ cell tumor via orchiectomy. Adjuvant chemotherapy with cisplatin, etoposide and bleomycin(BEP)was initiated. He developed a headache 8 days later, followed by neurological deficits 10 days later. Magnetic resonance imaging(MRI)and magnetic resonance venography(MRV)showed thrombotic occlusion at the superior sagittal sinus. Anticoagulant therapy with heparin was initiated. However, a generalized epileptic seizure occurred 11 days later, and an antiepileptic drug therapy was initiated...
May 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28486478/effect-of-chronic-estradiol-plus-progesterone-treatment-on-experimental-arterial-and-venous-thrombosis-in-mouse
#12
Marie-Cécile Valéra, Emmanuelle Noirrit-Esclassan, Marion Dupuis, Melissa Buscato, Alexia Vinel, Maeva Guillaume, Anne Briaux, Cédric Garcia, Thibaut Benoit, Olivier Lairez, Coralie Fontaine, Bernard Payrastre, Jean-François Arnal
Postmenopausal hormone replacement therapy (HRT) with estrogen plus progestogens is the first line therapy to treat menopausal symptoms. The progestogen is added to estrogen to reduce or eliminate the excess risk of endometrial cancer due to the unopposed effect of estrogen. Whereas progestin clearly opposes the proliferative and deleterious long-term actions of estrogen on the endometrium, the interference of progestin on the other estrogen action remains unclear. We previously reported that chronic subcutaneous 17α-estradiol (E2) in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism...
2017: PloS One
https://www.readbyqxmd.com/read/28486358/incidence-and-timing-of-thromboembolic-events-in-patients-with-ovarian-cancer-undergoing-neoadjuvant-chemotherapy
#13
Patricia S Greco, Ali A Bazzi, Karen McLean, R Kevin Reynolds, Ryan J Spencer, Carolyn M Johnston, J Rebecca Liu, Shitanshu Uppal
OBJECTIVE: To identify the incidence and timing of venous thromboembolism as well as any associated risk factors in patients with ovarian, fallopian tube, or primary peritoneal cancer undergoing neoadjuvant chemotherapy. METHODS: We conducted a retrospective cohort study of patients diagnosed with ovarian, fallopian tube, and primary peritoneal cancer and receiving neoadjuvant chemotherapy from January 2009 to May 2014 at a single academic institution. The timing and number of venous thromboembolic events for the entire cohort were categorized as follows: presenting symptom, during neoadjuvant chemotherapy treatment, after debulking surgery, and during adjuvant chemotherapy...
May 5, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28483766/how-i-treat-recurrent-venous-thromboembolism-in-patients-on-anticoagulant-therapy
#14
Sam Schulman
Oral anticoagulant therapy for venous thromboembolism (VTE) is very effective. When oral anticoagulants are managed well, the risk of recurrence is approximately 2 per 100 patient-years. The main reasons for a breakthrough event can be split into underlying disease and subtherapeutic drug levels. The most common underlying disease that results in recurrence on treatment is cancer. Subtherapeutic drug levels can be caused by poor adherence to the drug regimen, interactions with other drugs or food, or inappropriate dosing...
May 8, 2017: Blood
https://www.readbyqxmd.com/read/28479450/perception-of-chemical-venous-thromboprophylaxis-for-oncologic-lung-resections-amongst-thoracic-surgeons
#15
Rafael D Malgor, Thomas V Bilfinger, John Blebea, Harry Ma, Shirliejean R Arnold
BACKGROUND: Controversies on chemical venous thromboembolic (VTE) prophylaxis in patients undergoing lung resection for malignancy exist. The available guidelines on VTE do not specifically address its prophylaxis in patients undergoing oncologic lung resections. The goal of this survey was to evaluate the perception of VTE prophylaxis amongst thoracic surgeons performing these operations. METHODS: A self-reported online survey was distributed to 267 active members of the General Thoracic Surgical Club between July and September 2015...
May 4, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28476911/risk-factors-for-venous-thromboembolism-in-patients-treated-for-differentiated-thyroid-carcinoma
#16
Trynke van der Boom, Esther N Klein Hesselink, Hilde A M Kooistra, Karina Meijer, Anouk N A van der Horst-Schrivers, Joop D Lefrandt, Thera P Links
Although cancer in general is a strong risk factor for developing venous thromboembolism (VTE), the risk factors for venous thromboembolic events in patients with differentiated thyroid carcinoma (DTC) have never been assessed. This is remarkable, as several parts of the treatment comprise a hypercoagulable state that could in subgroups of DTC patients lead to an increased risk of VTE. The aim of this study was to assess which risk factors could cause DTC patients to develop VTE. We performed a nested case-control study, involving cases of DTC patients treated between 1980 and 2014 with confirmed VTE after diagnosis of DTC...
June 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28470575/association-between-level-of-tumor-markers-and-development-of-vte-in-patients-with-pancreatic-colorectal-and-ovarian-ca-retrospective-case-control-study-in-two-community-hospitals
#17
Nelly Awkar, Sawsan Amireh, Srijana Rai, Hamid Shaaban, Gunwant Guron, Michael Maroules
The risk of venous thromboembolism (VTE) is increased in patients with cancer. However, the role of tumor markers as potential indicators of increased risk of VTE is still undetermined. In this retrospective observational case control study, levels of the tumor markers CEA, CA 19-9 and CA 125 in patients with colorectal, pancreatic, and ovarian cancer respectively, who were admitted to two community hospitals between January 2001 and December 2011, were compared between patients who were VTE positive and those who were VTE negative...
May 4, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28468786/long-term-effects-of-unprovoked-venous-thromboembolism-on-mortality-and-major-cardiovascular-events
#18
Wei-Ting Chang, Chia-Li Chang, Chung-Han Ho, Chon-Seng Hong, Jhi-Joung Wang, Zhih-Cherng Chen
BACKGROUND: Patients with unprovoked venous thromboembolism (VTE) are at an increased risk of mortality, but whether their cardiovascular risks also increase remains to be determined. We aimed to investigate the factors associated with overall mortality and major adverse cardiovascular events in patients with unprovoked VTE. METHODS AND RESULTS: We identified 2154 patients newly diagnosed with unprovoked VTE from Taiwan's National Health Insurance Database between 2000 and 2013, excluding those with reversible etiologies, underlying cancer, or autoimmune diseases...
May 3, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28467466/outcomes-and-prognoses-of-patients-with-ovarian-cancer-using-bevacizumab-6-year-experience-in-a-tertiary-care-hospital-of-northern-taiwan
#19
Wei-Chun Chen, Jiantai Timothy Qiu, Chyong-Huey Lai, Huei-Jean Huang, Cheng-Tao Lin, Min-Yu Chen, Hung-Hsueh Chou, Kuan-Gen Huang, Ting-Chang Chang
PURPOSE: Bevacizumab (BEV) has been used for ovarian cancer (OC) for years in Taiwan, but the associated data related to outcome is scant. This retrospective study reviewed patients with OC treated with BEV and analyzed their results. PATIENTS AND METHODS: All patients with OC treated with BEV from 2009 to 2015 in the Linkou branch of Chang Gung Memorial Hospital in Northern Taiwan were included. According to the means of administration, the patients were classified into 6 groups as follows: A-BEV plus chemotherapy (C/T) for initial platinum-resistant (PR) recurrent OC, B-BEV plus C/T for initial platinum-sensitive (PS) recurrent OC, C-BEV alone for recurrent OC, D-BEV plus 1st adjuvant C/T, E-BEV plus neoadjuvant C/T, and F-intraperitoneal (IP) BEV...
2017: PloS One
https://www.readbyqxmd.com/read/28463030/use-of-cyproterone-acetate-ethinylestradiol-in-polycystic-ovary-syndrome-rationale-and-practical-aspects
#20
X Ruan, A Kubba, A Aguilar, A O Mueck
INTRODUCTION: Polycystic ovary syndrome (PCOS) is a common, heterogeneous disorder characterised by hyperandrogenic skin symptoms, irregular menstruation and subfertility, increased risk of endometrial malignancy, and increased risk of preventable diseases associated with metabolic syndrome. Cyproterone acetate (CPA) 2 mg, combined with ethinylestradiol (EE) 35 μg, is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age...
May 2, 2017: European Journal of Contraception & Reproductive Health Care
keyword
keyword
39888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"